A citation-based method for searching scientific literature

Jennifer H Lingler, William E Klunk. Alzheimers Dement 2013
Times Cited: 29







List of co-cited articles
173 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Amyloid imaging, risk disclosure and Alzheimer's disease: ethical and practical issues.
J Scott Roberts, Laura B Dunn, Gil D Rabinovici. Neurodegener Dis Manag 2013
31
51

Disclosure of APOE genotype for risk of Alzheimer's disease.
Robert C Green, J Scott Roberts, L Adrienne Cupples, Norman R Relkin, Peter J Whitehouse, Tamsen Brown, Susan LaRusse Eckert, Melissa Butson, A Dessa Sadovnick, Kimberly A Quaid,[...]. N Engl J Med 2009
317
48

Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association.
Keith A Johnson, Satoshi Minoshima, Nicolaas I Bohnen, Kevin J Donohoe, Norman L Foster, Peter Herscovitch, Jason H Karlawish, Christopher C Rowe, Maria C Carrillo, Dean M Hartley,[...]. Alzheimers Dement 2013
279
44

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
Reisa A Sperling, Paul S Aisen, Laurel A Beckett, David A Bennett, Suzanne Craft, Anne M Fagan, Takeshi Iwatsubo, Clifford R Jack, Jeffrey Kaye, Thomas J Montine,[...]. Alzheimers Dement 2011
41

The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
Marilyn S Albert, Steven T DeKosky, Dennis Dickson, Bruno Dubois, Howard H Feldman, Nick C Fox, Anthony Gamst, David M Holtzman, William J Jagust, Ronald C Petersen,[...]. Alzheimers Dement 2011
41

Should we disclose amyloid imaging results to cognitively normal individuals?
Joshua D Grill, David K Johnson, Jeffrey M Burns. Neurodegener Dis Manag 2013
23
47

Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants.
Kristin Harkins, Pamela Sankar, Reisa Sperling, Joshua D Grill, Robert C Green, Keith A Johnson, Megan Healy, Jason Karlawish. Alzheimers Res Ther 2015
50
37

Development of a Standardized Approach to Disclosing Amyloid Imaging Research Results in Mild Cognitive Impairment.
Jennifer H Lingler, Meryl A Butters, Amanda L Gentry, Lu Hu, Amanda E Hunsaker, William E Klunk, Meghan K Mattos, Lisa S Parker, J Scott Roberts, Richard Schulz. J Alzheimers Dis 2016
22
45

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
Guy M McKhann, David S Knopman, Howard Chertkow, Bradley T Hyman, Clifford R Jack, Claudia H Kawas, William E Klunk, Walter J Koroshetz, Jennifer J Manly, Richard Mayeux,[...]. Alzheimers Dement 2011
31

Disclosure of positron emission tomography amyloid imaging results: A preliminary study of safety and tolerability.
Yen Ying Lim, Paul Maruff, Christine Getter, Peter J Snyder. Alzheimers Dement 2016
35
31

Using AD biomarker research results for clinical care: a survey of ADNI investigators.
Melanie B Shulman, Kristin Harkins, Robert C Green, Jason Karlawish. Neurology 2013
27
29


The A4 study: stopping AD before symptoms begin?
Reisa A Sperling, Dorene M Rentz, Keith A Johnson, Jason Karlawish, Michael Donohue, David P Salmon, Paul Aisen. Sci Transl Med 2014
422
27

Clinical use of amyloid-positron emission tomography neuroimaging: Practical and bioethical considerations.
Michael M Witte, Norman L Foster, Adam S Fleisher, Monique M Williams, Kimberly Quaid, Michael Wasserman, Gail Hunt, J Scott Roberts, Gil D Rabinovici, James L Levenson,[...]. Alzheimers Dement (Amst) 2015
24
33

Safety of disclosing amyloid status in cognitively normal older adults.
Jeffrey M Burns, David K Johnson, Edward P Liebmann, Rebecca J Bothwell, Jill K Morris, Eric D Vidoni. Alzheimers Dement 2017
36
27

Communicating mild cognitive impairment diagnoses with and without amyloid imaging.
Joshua D Grill, Liana G Apostolova, Szofia Bullain, Jeffrey M Burns, Chelsea G Cox, Malcolm Dick, Dean Hartley, Claudia Kawas, Sarah Kremen, Jennifer Lingler,[...]. Alzheimers Res Ther 2017
30
24

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.
Bruno Dubois, Howard H Feldman, Claudia Jacova, Harald Hampel, José Luis Molinuevo, Kaj Blennow, Steven T DeKosky, Serge Gauthier, Dennis Selkoe, Randall Bateman,[...]. Lancet Neurol 2014
24

Patient and caregiver reactions to clinical amyloid imaging.
Joshua D Grill, Chelsea G Cox, Sarah Kremen, Mario F Mendez, Edmond Teng, Jill Shapira, John M Ringman, Liana G Apostolova. Alzheimers Dement 2017
19
36

Clinical and biomarker changes in dominantly inherited Alzheimer's disease.
Randall J Bateman, Chengjie Xiong, Tammie L S Benzinger, Anne M Fagan, Alison Goate, Nick C Fox, Daniel S Marcus, Nigel J Cairns, Xianyun Xie, Tyler M Blazey,[...]. N Engl J Med 2012
20

Dementia specialists and early adoption of amyloid imaging.
Eran P Klein, Jeffrey Kaye. J Alzheimers Dis 2013
12
50

Attitudes of Research Participants and the General Public Regarding Disclosure of Alzheimer Disease Research Results.
Jonathan Gooblar, Catherine M Roe, Natalie J Selsor, Matthew J Gabel, John C Morris. JAMA Neurol 2015
20
30

Psychological, behavioral and social effects of disclosing Alzheimer's disease biomarkers to research participants: a systematic review.
S A S A Bemelmans, K Tromp, E M Bunnik, R J Milne, S Badger, C Brayne, M H Schermer, E Richard. Alzheimers Res Ther 2016
33
20

Amnestic MCI patients' experiences after disclosure of their amyloid PET result in a research context.
Gwendolien Vanderschaeghe, Jolien Schaeverbeke, Rose Bruffaerts, Rik Vandenberghe, Kris Dierickx. Alzheimers Res Ther 2017
13
46

Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease.
D S Knopman, C R Jack, H J Wiste, S D Weigand, P Vemuri, V Lowe, K Kantarci, J L Gunter, M L Senjem, R J Ivnik,[...]. Neurology 2012
195
17

Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study.
Christopher M Clark, Michael J Pontecorvo, Thomas G Beach, Barry J Bedell, R Edward Coleman, P Murali Doraiswamy, Adam S Fleisher, Eric M Reiman, Marwan N Sabbagh, Carl H Sadowsky,[...]. Lancet Neurol 2012
484
17

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria.
Bruno Dubois, Howard H Feldman, Claudia Jacova, Steven T Dekosky, Pascale Barberger-Gateau, Jeffrey Cummings, André Delacourte, Douglas Galasko, Serge Gauthier, Gregory Jicha,[...]. Lancet Neurol 2007
17

Diagnosis and management of Alzheimer's disease: past, present and future ethical issues.
S Gauthier, A Leuzy, E Racine, P Rosa-Neto. Prog Neurobiol 2013
50
17

Effect of knowledge of APOE genotype on subjective and objective memory performance in healthy older adults.
Tara T Lineweaver, Mark W Bondi, Douglas Galasko, David P Salmon. Am J Psychiatry 2014
60
17

Preclinical Alzheimer disease-the challenges ahead.
Reisa A Sperling, Jason Karlawish, Keith A Johnson. Nat Rev Neurol 2013
159
17

Genetic risk assessment for adult children of people with Alzheimer's disease: the Risk Evaluation and Education for Alzheimer's Disease (REVEAL) study.
J Scott Roberts, L Adrienne Cupples, Norman R Relkin, Peter J Whitehouse, Robert C Green. J Geriatr Psychiatry Neurol 2005
93
17

Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers.
Clifford R Jack, David S Knopman, William J Jagust, Ronald C Petersen, Michael W Weiner, Paul S Aisen, Leslie M Shaw, Prashanthi Vemuri, Heather J Wiste, Stephen D Weigand,[...]. Lancet Neurol 2013
17

Use of amyloid PET across the spectrum of Alzheimer's disease: clinical utility and associated ethical issues.
Antoine Leuzy, Eduardo Rigon Zimmer, Kerstin Heurling, Pedro Rosa-Neto, Serge Gauthier. Amyloid 2014
23
21

Ethics of genetic and biomarker test disclosures in neurodegenerative disease prevention trials.
Scott Y H Kim, Jason Karlawish, Benjamin E Berkman. Neurology 2015
28
17


A Survey of Knowledge and Views Concerning Genetic and Amyloid PET Status Disclosure.
B R Ott, M A Pelosi, G Tremont, P J Snyder. Alzheimers Dement (N Y) 2016
15
33

Ethical challenges in preclinical Alzheimer's disease observational studies and trials: Results of the Barcelona summit.
José L Molinuevo, Jordi Cami, Xavier Carné, Maria C Carrillo, Jean Georges, Maria B Isaac, Zaven Khachaturian, Scott Y H Kim, John C Morris, Florence Pasquier,[...]. Alzheimers Dement 2016
28
17

Amnestic MCI Patients' Perspectives toward Disclosure of Amyloid PET Results in a Research Context.
Gwendolien Vanderschaeghe, Jolien Schaeverbeke, Rik Vandenberghe, Kris Dierickx. Neuroethics 2017
10
50

Comprehension of an Elevated Amyloid Positron Emission Tomography Biomarker Result by Cognitively Normal Older Adults.
Jessica Mozersky, Pamela Sankar, Kristin Harkins, Sara Hachey, Jason Karlawish. JAMA Neurol 2018
30
17

Amyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer's disease.
Rik Vandenberghe, Katarzyna Adamczuk, Patrick Dupont, Koen Van Laere, Gaël Chételat. Neuroimage Clin 2013
67
13

Frequent amyloid deposition without significant cognitive impairment among the elderly.
Howard Jay Aizenstein, Robert D Nebes, Judith A Saxton, Julie C Price, Chester A Mathis, Nicholas D Tsopelas, Scott K Ziolko, Jeffrey A James, Beth E Snitz, Patricia R Houck,[...]. Arch Neurol 2008
707
13

Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease.
Gaël Chételat, Renaud La Joie, Nicolas Villain, Audrey Perrotin, Vincent de La Sayette, Francis Eustache, Rik Vandenberghe. Neuroimage Clin 2013
196
13

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B.
William E Klunk, Henry Engler, Agneta Nordberg, Yanming Wang, Gunnar Blomqvist, Daniel P Holt, Mats Bergström, Irina Savitcheva, Guo-feng Huang, Sergio Estrada,[...]. Ann Neurol 2004
13

Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors.
Jill S Goldman, Susan E Hahn, Jennifer Williamson Catania, Susan LaRusse-Eckert, Melissa Barber Butson, Malia Rumbaugh, Michelle N Strecker, J Scott Roberts, Wylie Burke, Richard Mayeux,[...]. Genet Med 2011
171
13

Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.
Victor L Villemagne, Samantha Burnham, Pierrick Bourgeat, Belinda Brown, Kathryn A Ellis, Olivier Salvado, Cassandra Szoeke, S Lance Macaulay, Ralph Martins, Paul Maruff,[...]. Lancet Neurol 2013
13

Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association.
Keith A Johnson, Satoshi Minoshima, Nicolaas I Bohnen, Kevin J Donohoe, Norman L Foster, Peter Herscovitch, Jason H Karlawish, Christopher C Rowe, Maria C Carrillo, Dean M Hartley,[...]. J Nucl Med 2013
153
13

Public perceptions of presymptomatic testing for Alzheimer disease.
Richard J Caselli, Jessica Langbaum, Gary E Marchant, Rachel A Lindor, Katherine S Hunt, Bruce R Henslin, Amylou C Dueck, Jason S Robert. Mayo Clin Proc 2014
31
13

Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study.
Stephanie Jb Vos, Chengjie Xiong, Pieter Jelle Visser, Mateusz S Jasielec, Jason Hassenstab, Elizabeth A Grant, Nigel J Cairns, John C Morris, David M Holtzman, Anne M Fagan. Lancet Neurol 2013
353
13

Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.
Willemijn J Jansen, Rik Ossenkoppele, Dirk L Knol, Betty M Tijms, Philip Scheltens, Frans R J Verhey, Pieter Jelle Visser, Pauline Aalten, Dag Aarsland, Daniel Alcolea,[...]. JAMA 2015
748
13

Timely Diagnosis for Alzheimer's Disease: A Literature Review on Benefits and Challenges.
Bruno Dubois, Alessandro Padovani, Philip Scheltens, Andrea Rossi, Grazia Dell'Agnello. J Alzheimers Dis 2016
170
13



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.